Biostar Granted Patent for Second TCM Hepatitis B Product

Biostar Pharmaceuticals received a China patent for Aoxing Ganbao, an external use TCM treatment for hepatitis B. Biostar already has name recognition in the hepatitis B sector with its flagship product, Xin Aoxing Oleanolic Acid Capsules. Xin Aoxing Oleanolic capsules, which is the only OTC oral hepatitis treatment product approved by the SFDA, generates about 50% of Biostar’s revenues. More details... Stock Symbol: (OTCBB: BSPM)